Nation sees therapeutics success
admin
2023-01-28 12:13:16
0

Pharmacists check prescription information at a fever clinic in Minhang district of Shanghai on Jan 8. The small molecule drugs to treat COVID-19 had been put into use in community health centers in Shanghai to better play their roles in "early detection, early intervention and early diversion". WANG XIANG/XINHUA

Domestically developed COVID-19 drug therapies lower risk of hospitalization

China will create broad-spectrum treatments to tackle mutated strains of the COVID-19 virus and develop drugs with novel mechanisms to fight the pathogen, according to a document provided to China Daily.

As of Jan 19, a total of 10 domestically made COVID-19 drugs had either been granted official or conditional market approval or were authorized to treat symptoms of the pathogen, the document stated.

The document was issued by the specialized team for COVID-19 medicine research and development under the Joint Prevention and Control Mechanism of the State Council, China's Cabinet.

China also had 23 drugs on the key COVID-19 medicine list that were in active development or undergoing real-world evidence studies after receiving market approval, it said.

"The team will continue to facilitate the development of safe and effective treatments that can cover the whole course of the disease and are suitable for all populations," it added.

Since the COVID-19 pandemic began, China's novel coronavirus drug development process has followed three broad technical paths- stopping the virus from entering cells, inhibiting viral replication in the body and regulating the body's immune system.

In December 2021, China granted official market approval to its first homegrown neutralizing monoclonal neutralizing antibody cocktails - BRII-196 and BRII-198. It is a combination therapy administered through intravenous infusion that can lower the risk of hospitalization and death by nearly 80 percent, according to its phase-three clinical trial results.

Meanwhile, Chinese scientists have been developing small-molecule oral treatments for COVID-19.A breakthrough came in July when China granted conditional authorization for the oral antiviral Azvudine to treat COVID-19. The drug was originally used to treat HIV.

This year, China will accelerate the development of small-molecule oral drugs. In mid-January, the National Medical Products Administration received applications for market approval for new antivirals SIM0417 and VV116. Another antiviral called RAY1216 had recently finished recruiting for its late-stage clinical trials.

Besides finding treatments for COVID-19, Chinese scientists are researching new drugs to prevent infections or regulate the body's immune system, with a handful of candidates currently in phase two or three clinical trials. Some notable examples include the targeted inhibitor drug TDI01 and HY3000 peptide nasal spray.

zhangzhihao@chinadaily.com.cn

相关内容

热门资讯

中证A500ETF摩根(560... 8月22日,截止午间收盘,中证A500ETF摩根(560530)涨1.19%,报1.106元,成交额...
A500ETF易方达(1593... 8月22日,截止午间收盘,A500ETF易方达(159361)涨1.28%,报1.104元,成交额1...
何小鹏斥资约2.5亿港元增持小... 每经记者|孙磊    每经编辑|裴健如 8月21日晚间,小鹏汽车发布公告称,公司联...
中证500ETF基金(1593... 8月22日,截止午间收盘,中证500ETF基金(159337)涨0.94%,报1.509元,成交额2...
中证A500ETF华安(159... 8月22日,截止午间收盘,中证A500ETF华安(159359)涨1.15%,报1.139元,成交额...
科创AIETF(588790)... 8月22日,截止午间收盘,科创AIETF(588790)涨4.83%,报0.760元,成交额6.98...
创业板50ETF嘉实(1593... 8月22日,截止午间收盘,创业板50ETF嘉实(159373)涨2.61%,报1.296元,成交额1...
港股异动丨航空股大幅走低 中国... 港股航空股大幅下跌,其中,中国国航跌近7%表现最弱,中国东方航空跌近5%,中国南方航空跌超3%,美兰...
电网设备ETF(159326)... 8月22日,截止午间收盘,电网设备ETF(159326)跌0.25%,报1.198元,成交额409....
红利ETF国企(530880)... 8月22日,截止午间收盘,红利ETF国企(530880)跌0.67%,报1.034元,成交额29.0...